KIT and neoplasm: In our study, including KIT exon 11, 13, and 17 mutation GISTs, which were truly well responsive to imatinib therapy at a dosage of 400 mg daily, KIT exon 9 mutation GISTs were also well responsive to imatinib therapy at a dosage of 600 mg daily, with obvious shrinkage of their tumor size.